{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:21:03Z","timestamp":1790191263830,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.10.076","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T07:41:32Z","timestamp":1668411692000},"page":"49-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50\u201364\u00a0years old in the United States"],"prefix":"10.1016","volume":"41","author":[{"given":"Jonathan","family":"Fix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja A.","family":"Vielot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Becker-Dreps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2022.10.076_b0005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice","volume":"347","author":"Gnann","year":"2002","journal-title":"Herpes zoster N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.076_b0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cger.2016.02.011","article-title":"Herpes Zoster","volume":"32","author":"Schmader","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"9","key":"10.1016\/j.vaccine.2022.10.076_b0015","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1742-1241.2009.02089.x","article-title":"Postherpetic neuralgia in the elderly","volume":"63","author":"Johnson","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"2 Suppl","key":"10.1016\/j.vaccine.2022.10.076_b0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ophtha.2007.10.009","article-title":"Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity","volume":"115","author":"Liesegang","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.vaccine.2022.10.076_b0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.076_b0030","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WNO.0000000000000721","article-title":"Neurological and Ophthalmological Manifestations of Varicella Zoster Virus","volume":"39","author":"Kedar","year":"2019","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.076_b0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2017.06.010","article-title":"Incidence of herpes zoster amongst adults varies by severity of immunosuppression","volume":"75","author":"Schroder","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2022.10.076_b0040","doi-asserted-by":"crossref","unstructured":"Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018;8(6):e020528.","DOI":"10.1136\/bmjopen-2017-020528"},{"issue":"9","key":"10.1016\/j.vaccine.2022.10.076_b0045","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vaccine.2022.10.076_b0050","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.076_b0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Solomon","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.076_b0060","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices Centers for Disease C, Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30; quiz CE32-34."},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.076_b0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"10.1016\/j.vaccine.2022.10.076_b0070","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.10.076_b0075","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.076_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"40","key":"10.1016\/j.vaccine.2022.10.076_b0085","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1016\/j.vaccine.2020.07.049","article-title":"A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349 year old patients","volume":"38","author":"Racine","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.076_b0090","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.076_b0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged >\/=19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.10.076_b0100","unstructured":"IBM. IBM MarketScan Research Databases. https:\/\/www.ibm.com\/products\/marketscan-research-databases. Accessed."},{"issue":"45","key":"10.1016\/j.vaccine.2022.10.076_b0105","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1016\/j.vaccine.2018.08.080","article-title":"Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals","volume":"36","author":"Meyers","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.076_b0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"issue":"8","key":"10.1016\/j.vaccine.2022.10.076_b0115","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3201\/eid2608.191493","article-title":"Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness","volume":"26","author":"Patel","year":"2020","journal-title":"United States Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.076_b0120","doi-asserted-by":"crossref","unstructured":"Wallace BI, Kenney B, Malani PN, Clauw DJ, Nallamothu BK, Waljee AK. Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019. JAMA Netw Open. 2021;4(5):e214920.","DOI":"10.1001\/jamanetworkopen.2021.4920"},{"key":"10.1016\/j.vaccine.2022.10.076_b0125","unstructured":"McEvoy GK, Snow EK, American Society of Health-System Pharmacists. AHFS drug information (2019). Bethesda, MD: Bethesda, MD : American Society of Health-System Pharmacists, [2019]; 2019."},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.076_b0130","doi-asserted-by":"crossref","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.076_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2022.10.076_b0140","article-title":"Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis","volume":"2021","author":"Patterson","year":"2003","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"10.1016\/j.vaccine.2022.10.076_b0145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","article-title":"Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older","volume":"39","author":"Ackerson","year":"2021","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2022.10.076_b0150","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1016\/j.vaccine.2021.04.053","article-title":"An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study","volume":"39","author":"McGirr","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.10.076_b0155","first-page":"426","article-title":"Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations","volume":"41","author":"Ventola","year":"2016","journal-title":"P T"},{"key":"10.1016\/j.vaccine.2022.10.076_b0160","unstructured":"Sun LH. New shingles vaccine is highly effective, long-lasting \u2014 and in short supply. The Washington Post. June 20, 2018, 2018;Health."},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.076_b0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2022.10.076_b0170","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.vaccine.2021.07.050","article-title":"Insurance reimbursements for recombinant zoster vaccine in the private sector","volume":"39","author":"Leidner","year":"2021","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:31Z","timestamp":1759404091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22013470"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50\u201364\u00a0years old in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}